Clinical Research Directory
Browse clinical research sites, groups, and studies.
Subjective Experience Following Psilocybin
Sponsor: University of Calgary
Summary
The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with either a placebo or risperidone, an atypical antipsychotic that block the subjective effects of psilocybin.
Official title: The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
128
Start Date
2026-05-15
Completion Date
2028-01
Last Updated
2026-05-22
Healthy Volunteers
Yes
Interventions
Psilocybin high-dose
The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose
Psilocybin low-dose
The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose.
Risperidone 1 MG
risperidone 1mg capsules
Placebo
inactive placebo
Locations (1)
University of Calgary
Calgary, Alberta, Canada